The pharmaceutical company Mayzent (siponimod) is a medication used to treat relapsing forms of multiple sclerosis (MS) in adults [1].
How is Mayzent Covered by Insurance?
Insurance coverage for Mayzent varies by plan. Many insurance providers offer coverage, but pre-authorization may be required [2]. Patients with commercial insurance may be eligible for the Mayzent Co-Pay Card, which can help reduce out-of-pocket costs, potentially lowering them to as little as $0 for a monthly prescription [2].
What is the Cost of Mayzent?
The retail price of Mayzent can be substantial, often exceeding $7,500 for a 30-day supply [3]. However, actual costs for patients depend on their insurance coverage, co-pay, deductible, and participation in any available patient assistance programs [2].
How Does Mayzent Work for MS?
Mayzent is a sphingosine-1-phosphate (S1P) receptor modulator. It works by trapping certain types of white blood cells (lymphocytes) in the lymph nodes, preventing them from entering the central nervous system and causing inflammation and damage to nerve cells in individuals with relapsing MS [1].
What Are the Side Effects of Mayzent?
Common side effects associated with Mayzent include headache, fatigue, nausea, dizziness, influenza, and increased liver enzymes [1]. More serious side effects can occur, such as a decrease in heart rate upon initiation of treatment, infections, vision problems, breathing problems, liver problems, and elevated blood pressure [1].
When Might Mayzent's Patent Expire?
Information regarding the specific patent expiry dates for Mayzent is not readily available. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can indicate when patent protection is set to end, potentially paving the way for generic alternatives [4].
Who Makes Mayzent?
Mayzent is developed and marketed by Novartis [1].
How Does Mayzent Compare to Other MS Treatments?
Mayzent is one of several disease-modifying therapies available for relapsing MS. Other treatments include other S1P receptor modulators like Gilenya (fingolimod), oral medications like Aubagio (teriflunomide) and Tecfidera (dimethyl fumarate), and injectable therapies like interferons and glatiramer acetate [5]. The choice of treatment depends on the specific type of MS, disease activity, patient preference, and tolerability of side effects [5].
Sources
1. https://www.mayzent.com/
2. https://www.mayzent.com/patients/financial-assistance
3. https://www.goodrx.com/mayzent
4. https://drugpatentwatch.com/
5. https://www.nationalmssociety.org/about-multiple-sclerosis/what-we-can-do/treatment-and-management/disease-modifying-therapies